Background: Knowledge about the molecular pathomechanisms of sarcopenia is still sparse, especially with regard to nutritional risk factors and the subtype of sarcopenic obesity. Objective: The aim of this study was to characterize diet-induced and age-related changes on the quality and quantity of the quadriceps muscle in a rat model of sarcopenia by different magnetic resonance (MR) techniques. Methods: A total of 36 6-month-old male Sprague-Dawley rats were randomly subdivided into 2 groups and received either a high-fat diet (HFD) or a control diet (CD). At the age of 16 months, 15 HFD and 18 CD rats underwent MR at 1.5 T. T1-weighted images as well as T2 relaxation time maps were acquired perpendicular to the long axis of the quadriceps muscles. Maximum cross-sectional area (CSA) of the quadriceps muscle was measured on T1-weighted images, and T2 relaxation times of muscle were assessed in a region without visible intramuscular fat (T2lean muscle) and across the complete CSA (T2muscle). Furthermore, 1H-MR spectroscopy was performed to evaluate the relative lipid content of the quadriceps muscles. These measurements were repeated 5 months later in the surviving 8 HFD and 14 CD rats. Results: HFD rats revealed significantly decreased CSA and CSA per body weight (BW) as well as prolonged T2 relaxation times of muscle. A higher weight gain (upper tertile during the first 6 months of diet in CD rats) resulted in a significant change of T2muscle, but had no relevant impact on CSA. Advancing age up to 21 months led to significantly decreased BW, CSA and CSA/BW, significantly prolonged T2muscle and T2lean muscle and enlarged lipid content in the quadriceps muscle. Conclusions: In an experimental setting a chronically fat-enriched diet was shown to have a relevant and age-associated influence on both muscle quantity and quality. By translational means the employed MR techniques give rise to the possibility of an early detection and noninvasive quantification of sarcopenia in humans, which is highly relevant for the field of geriatrics.

1.
Cooper C, Dere W, Evans W, Kanis JA, Rizzoli R, Sayer AA, Sieber CC, Kaufman JM, van Kan GA, Boonen S, Adachi J, Mitlak B, Tsouderos Y, Rolland Y, Reginster JY: Frailty and sarcopenia: definitions and outcome parameters. Osteoporos Int 2012;23:1839-1848.
2.
Rolland Y, Lauwers-Cances V, Cristini C, van Kan GA, Janssen I, Morley JE, Vellas B: Difficulties with physical function associated with obesity, sarcopenia, and sarcopenic-obesity in community-dwelling elderly women: the EPIDOS (EPIDemiologie de l'OSteoporose) Study. Am J Clin Nutr 2009;89:1895-1900.
3.
Zamboni M, Mazzali G, Fantin F, Rossi A, Di Francesco V: Sarcopenic obesity: a new category of obesity in the elderly. Nutr Metab Cardiovasc Dis 2008;18:388-395.
4.
Li Z, Heber D: Sarcopenic obesity in the elderly and strategies for weight management. Nutr Rev 2012;70:57-64.
5.
Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel JP, Rolland Y, Schneider SM, Topinková E, Vandewoude M, Zamboni M: Sarcopenia: European consensus on definition and diagnosis: report of the European working group on sarcopenia in older people. Age Ageing 2010;39:412-423.
6.
Sakuma K, Yamaguchi A: Sarcopenic obesity and endocrinal adaptation with age. Int J Endocrinol 2013;2013:204164.
7.
Turpin SM, Ryall JG, Southgate R, Darby I, Hevener AL, Febbraio MA, Kemp BE, Lynch GS, Watt MJ: Examination of ‘lipotoxicity' in skeletal muscle of high-fat fed and ob/ob mice. J Physiol 2009;587:1593-1605.
8.
Bollheimer LC, Buettner R, Pongratz G, Brunner-Ploss R, Hechtl C, Banas M, Singler K, Hamer OW, Stroszczynski C, Sieber CC, Fellner C: Sarcopenia in the aging high-fat fed rat: a pilot study for modeling sarcopenic obesity in rodents. Biogerontology 2012;13:609-620.
9.
Visser M, Goodpaster BH, Kritchevsky SB, Newman AB, Nevitt M, Rubin SM, Simonsick EM, Harris TB: Muscle mass, muscle strength, and muscle fat infiltration as predictors of incident mobility limitations in well-functioning older persons. J Gerontol A Biol Sci Med Sci 2005;60:324-333.
10.
Ratkevicius A, Joyson A, Selmer I, Dhanani T, Grierson C, Tommasi AM, De Vries A, Rauchhaus P, Crowther D, Alesci S, Yaworsky P, Gilbert F, Redpath TW, Brady J, Fearon KC, Reid DM, Greig CA, Wackerhage H: Serum concentrations of myostatin and myostatin-interacting proteins do not differ between young and sarcopenic elderly men. J Gerontol A Biol Sci Med Sci 2011;66:620-626.
11.
Delmonico MJ, Harris TB, Visser M, Park SW, Conroy MB, Velasquez-Mieyer P, Boudreau R, Manini TM, Nevitt M, Newman AB, Goodpaster BH: Longitudinal study of muscle strength, quality, and adipose tissue infiltration. Am J Clin Nutr 2009;90:1579-1585.
12.
Schwenzer N, Martirosian P, Machann J, Schraml C, Steidle G, Claussen CD, Schick F: Aging effects on human calf muscle properties assessed by MRI at 3 T. J Magn Reson Imaging 2009;29:1346-1354.
13.
Kuhlmann J, Neumann-Haefelin C, Belz U, Kramer W, Juretschke HP, Herling AW: Correlation between insulin resistance and intramyocellular lipid levels in rats. Magn Reson Med 2005;53:1275-1282.
14.
Boettcher M, Machann J, Stefan N, Thamer C, Häring HU, Claussen CD, Fritsche A, Schick F: Intramuscular adipose tissue (IMAT): association with other adipose tissue compartments and insulin sensitivity. J Magn Reson Imaging 2009;29:1340-1345.
15.
Schrauwen-Hinderling VB, Hesselink MKC, Schrauwen P, Kooi ME: Intramyocellular lipid content in human skeletal muscle. Obesity 2006;14:357-367.
16.
Boesch C, Slotboom J, Hoppeler H, Kreis R: In vivo determination of intra-myocellular lipids in human muscle by means of localized 1H-MR spectroscopy. Magn Reson Med 1997;37:484-493.
17.
Boesch C, Machann J, Vermathen P, Schick F: Role of proton MR for the study of muscle lipid metabolism. NMR Biomed 2006;19:968-988.
18.
Saukkonen T, Heikkinen S, Hakkarainen A, Häkkinen AM, van Leemput K, Lipsanen-Nyman M, Lundbom N: Association of intramyocellular, intraperitoneal and liver fat with glucose tolerance in severely obese adolescents. Eur J Endocrinol 2010;163:413-419.
19.
Johannsen DL, Conley KE, Bajpeyi S, Punyanitya M, Gallagher D, Zhang Z, Covington J, Smith SR, Ravussin E: Ectopic lipid accumulation and reduced glucose tolerance in elderly adults are accompanied by altered skeletal muscle mitochondrial activity. J Clin Endocrinol Metab 2012;97:242-250.
20.
Takahashi K, Takahashi HE, Nakadaira H, Yamamoto M: Different changes of quantity due to aging in the psoas major and quadriceps femoris muscles in women. J Musculoskelet Neuronal Interact 2006;6:201-205.
21.
Hatakenaka M, Ueda M, Ishigami K, Otsuka M, Masuda K: Effects of aging on muscle T2 relaxation time difference between fast- and slow-twitch muscles. Invest Radiol 2001;36:692-698.
22.
Nakagawa Y, Hattori M, Harada K, Shirase R, Bando M, Okano G: Age-related changes in intramyocellular lipid in humans by in vivo 1H-MR spectroscopy. Gerontology 2007;53:218-223.
23.
Bredella MA, Ghomi RH, Thomas BJ, Miller KK, Torriani M: Comparison of 3.0 T proton magnetic resonance spectroscopy short and long echo-time measures of intramyocellular lipids in obese and normal-weight women. J Magn Reson Imaging 2010;32:388-393.
24.
Lexell J: Human aging, muscle mass, and fiber type composition. J Gerontol A Biol Sci Med Sci 1995;50:11-16.
25.
Gloor M, Fasler S, Fischmann A, Haas T, Bieri O, Heinimann K, Wetzel SG, Scheffler K, Fischer D: Quantification of fat infiltration in oculopharyngeal muscular dystrophy: comparison of three MR imaging methods. J Magn Reson Imaging 2011;33:203-210.
26.
De Feyter HM, Lenaers E, Houten SM, Schrauwen P, Hesselink MK, Wanders RJ, Nicolay K, Prompers JJ: Increased intramyocellular lipid content but normal skeletal muscle mitochondrial oxidative capacity throughout the pathogenesis of type 2 diabetes. FASEB J 2008;22:3947-3955.
27.
van den Broek NM, Ciapaite J, De Feyter HM, Houten SM, Wanders RJ, Jeneson JA, Nicolay K, Prompers JJ: Increased mitochondrial content rescues in vivo muscle oxidative capacity in long-term high-fat-diet-fed rats. FASEB J 2010;24:1354-1364.
28.
Beha A, Juretschke HP, Kuhlmann J, Neumann-Haefelin C, Belz U, Gerl M, Kramer W, Roden M, Herling AW: Muscle type-specific fatty acid metabolism in insulin resistance: an integrated in vivo study in Zucker diabetic fatty rats. Am J Physiol Endocrinol Metab 2006;290:E989-E997.
29.
Conley KE, Cress ME, Jubrias SA, Esselman PC, Odderson IR: From muscle properties to human performance, using magnetic resonance. J Gerontol A Biol Sci Med Sci 1995;50:35-40.
30.
Nicolato E, Farace P, Asperio RM, Marzola P, Lunati E, Sbarbati A, Osculati F: Dynamic contrast-enhanced magnetic resonance imaging of the sarcopenic muscle. BMC Med Imaging 2002;2:2.
31.
Neumann-Haefelin C, Kuhlmann J, Belz U, Kalisch J, Quint M, Gerl M, Juretschke HP, Herling AW: Determinants of intramyocellular lipid concentrations in rat hindleg muscle. Magn Reson Med 2003;50:242-248.
32.
Machann J, Thamer C, Stefan N, Schwenzer NF, Kantartzis K, Häring HU, Claussen CD, Fritsche A, Schick F: Follow-up whole-body assessment of adipose tissue compartments during a lifestyle intervention in a large cohort at increased risk for type 2 diabetes. Radiology 2010;257:353-363.
33.
Reisz-Porszasz S, Bhasin S, Artaza JN, Shen R, Sinha-Hikim I, Hogue A, Fielder TJ, Gonzalez-Cadavid NF: Lower skeletal muscle mass in male transgenic mice with muscle-specific overexpression of myostatin. Am J Physiol Endocrinol Metab 2003;285:E876-E888.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.